Siegfried announced on June 13 that it was expanding its global contract development management organization (CDMO) abilities with the acquisition of an early-phase manufacturing site in Grafton, Wisconsin from Curia Global.
The Wisconsin facility specializes in early-phase development and manufacturing services and employs more than 80 workers.
Siegfried develops and manufactures active pharmaceutical ingredients for pharmaceutical clients with R&D programs, related intermediates and controlled substances. Siegfried also offers the development and production of finished dosage forms, including sterile fillings. It is based in Zofingen, Switzerland.
Curia Global is a global CDMO with headquarters in Albany, New York. It provides drug discovery, development, cGMP manufacturing and aseptic fill and finish to the pharmaceutical and biotechnology industries.
Siegfried said it plans to develop the site into a hub for early-phase CDMO services for its global customers, which will include services for projects with highly potent drug ingredients. The financial terms were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 16th CDMO transaction of 2024. Throughout 2023, there were 21 CDMO transactions reported.
